NovaScan study shows rapid AI-guided margin assessment in Mohs surgery

NovaScan says a peer-reviewed Nature Portfolio study found strong performance for its MarginScan platform in Mohs surgery for nodular basal cell carcinoma. The company is preparing additional skin cancer studies, a pivotal trial and an FDA submission as it expands beyond dermatology.

Why it matters: - Mohs surgery depends on accurate margin assessment, but frozen section pathology can slow workflow and create bottlenecks in busy clinics. - NovaScan’s non-destructive system is designed to give surgeons earlier spatial information while preserving histopathology as the standard for final margin clearance. - The platform could shorten decision-making in dermatology and support NovaScan’s broader point-of-care cancer assessment strategy.

What happened: - NovaScan announced publication of a peer-reviewed study in npj Biomedical Innovations, a Nature Portfolio journal. - The paper, “Machine learning-guided bioelectrical impedance mapping for rapid adjunctive margin assessment in Mohs surgery,” evaluated NovaScan’s MarginScan platform in Mohs micrographic surgery. - The study focused on excised dermal specimens from patients undergoing Mohs surgery for nodular basal cell carcinoma. - The publication appeared in 2026.

The details: - MarginScan combines high-frequency bioelectrical impedance spectroscopy with supervised machine learning. - The system translates impedance measurements into spatial probability heat maps that estimate the risk of cancer-positive tissue at the surgical margin. - The technology is intended as an adjunct to histopathology, not a replacement. - Under spatial-tolerance scoring, MarginScan achieved a mean ROC AUC of 0.993 ± 0.003. - The study reported 95.6% ± 4.7% sensitivity and 96.1% ± 5.0% specificity. - Median acquisition time was 3.7 minutes per specimen. - The authors concluded the technology can fit into the Mohs staging workflow without materially extending the grossing-to-histology interval. - Because MarginScan is non-destructive, specimens still move through standard frozen section pathology after scanning. - NovaScan said the work supports a clinical and regulatory path in dermatology. - NovaScan is also advancing additional skin cancer studies, a pivotal trial and an FDA submission for MarginScan. - NovaScan is developing applications beyond dermatology, including breast-conserving surgery. - The company said that expansion is supported by a $3.7 million CPRIT Product Development Award. - MarginScan is an investigational device and has not been cleared or approved by the U.S. Food and Drug Administration. - The publication is available here. - NovaScan also shared company updates on LinkedIn.

Between the lines: - The study’s strength is not just accuracy, but speed and workflow compatibility. - The reported performance suggests AI-guided impedance mapping may be useful as an early-warning tool before frozen sections are finalized. - The larger test will be whether the results hold in bigger, multi-center studies and in routine clinical use.

What's next: - NovaScan plans additional skin cancer studies and a pivotal trial before an FDA submission for MarginScan. - The company is expected to continue building evidence for dermatology use while exploring breast surgery and other oncology applications. - Further validation will determine whether the platform can move from investigational promise to clinical adoption.